2019年3期
Cancer Drug Resistance
Review
- Cancer drug resistance:rationale for drug delivery systems and targeted inhibition of HSP90 family proteins
- Circulating non-coding RNAs in recurrent and metastatic ovarian cancer
- Computational analyses for cancer biology based on exhaustive experimental backgrounds
- Dodging the bullet:therapeutic resistance mechanisms in pediatric cancers
- Drug-adapted cancer cell lines as preclinical models of acquired resistance
- Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets
- Emerging consensus on the mechanism of polyspecific substrate recognition by the multidrug transporter P-glycoprotein
- Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies
- lnnate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers
- lnsights into breast cancer phenotying through molecular omics approaches and therapy response
- lnvolvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
- Long non-coding RNAs regulation of therapeutic resistance
- Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy
- Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors
- Mechanisms of resistance to anti-angiogenic treatments
- Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
- MicroRNAs and cancer drug resistance:over two thousand characters in search of a role
- Mitochondrial determinants of chemoresistance
- Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies
- PARP inhibitors:clinical development,emerging differences,and the current therapeutic issues
- Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
- Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators
- Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
- Role of circulating tumor cell spheroids in drug resistance
- Stress and drug resistance in cancer
- Tailored therapy in patients treated with fluoropyrimidines:focus on the role of dihydropyrimidine dehydrogenase
- Targeting MYCN and ALK in resistant and relapsing neuroblastoma
- Targeting the “undruggable” RAS - new strategies - new hope?
- The effects of growth hormone on therapy resistance in cancer
- The role of exosomal microRNAs; focus on clinical applications in breast cancer
- Use of MRl,metabolomic,and genomic biomarkers to identify mechanisms of chemoresistance in glioma
Original Article
- Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy
- MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
- Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells:the quest for microRNAs' involvement in cancer drug resistance